List of publications Creativ-Ceutical

(Updated February 2014)

A. Peer reviewed journal articles


B. Abstracts


(11) Desroziers, K., Aballea, S., Maman, K., Nazir, J., Odeyemi, I., and Hakimi, Z. (1-5-2013). Estimation and comparison of utilities generated from a generic (EQ-5D) and disease-specific (OAB-5D) instrument in an overactive bladder population. Value Health 16[3], A182


(14) Ferchichi, S., Aballea, S., Goryakin, Y., Hakimi, Z., Odeyemi, I., and Toumi, M. (1-5-2013). A Retrospective Study On The Burden Of Cytomegalovirus Disease In Immunosuppressed Persons Following Transplantation Between 2007 And 2011 In France. Value Health 16[3], A82


(16) Guelfucci, F., Neine, M., Bineau, S., Milea, D., and Aballea, S. (1-11-2013). Description of Treatment Pathways in Chronic Diseases Using Large General Practitioner Longitudinal Data: The Example of Pharmaco-Therapy in Parkinson's Disease in the United Kingdom. Value Health 16[7], A583


(27) Maman, K., Aballea, S., Nazir, J., Desroziers, K., Neine, M., Siddiqui, E., Odeyemi, I., and Hakimi, Z. (1-5-2013). Comparative efficacy and safety of treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison. *Value Health* 16[3], A180


Psychiatrists From Different Countries in Major Depressive Disorder. *American Psychiatric Association Congress, 18-22 May, San Francisco, CA, USA*


(53) Clay, E., Zah, V., Ruby, J., and Aballea, S. (2012). Patient Persistence with Buprenorphine/Naloxone Film and Tablet Formulations in the Treatment of Opioid Dependence in the United States: Results from a Privately Insured Retrospective Database. *36th annual Association for Medical Education and Research in Substance Abuse (AMERSA), 1-3 November 2012, Bethesda, MD, USA*


Clay, E., Mraidi, M., Zielonka, D., Cohen, J., Toumi, M., and Auquier, P. (1-11-2011). PND46: The Huntington Quality of Life Instrument (H-QOL-I): Cross-Cultural Validation in Germany, Poland and USA. *Value Health* 14[7], A325-A326


(117) Siani, C., de Peretti, C., Millier, A., and Toumi, M. (2011). Relationship between utility and the positive and negative syndrome scale for schizophrenia in the United Kingdom, France and Germany findings from the European Schizophrenia Cohort (EuroSC). *iHEA 8th World Congress on Health Economics, 10-13 July 2011, Toronto, Canada*


(134) Hemels, M., Jensen, R. C. Ä, Toumi, M., and Adalsteinsson, E. (1-5-2010). PDB6: Relative effectiveness management of type II diabetes in Europe: can the agencies' demands be met? *Value Health* 13[3], A55


(138) Lim, B. K., Toh, M., Jong, M., Chionh, S. B., and Sum, C. F. (1-11-2010). PDB25: Diabetes-related complications and glycemic control in type 2 diabetic mellitus patients at specialist outpatient clinics in Singapore. *Value Health* 13[7], A530-A531


and severe Alzheimer's disease patients with agitation, aggression and psychosis: the UK example. *Value Health* **13**(7), A452


(144) Toumi, M. and Jaroslawski, S. (1-11-2010). NI2: Patient access schemes in UK are driven by Health Technology Assessment. *Value Health* **13**(7), A246


(157) Saragoussi, D., Guilhaume, C., Dorey, J., and Toumi, M. (1-10-2009). PCV70: Management of acute ischemic stroke (is) and associated costs over a 12-month period in France. *Value Health* 12[7], A325


(211) Azorin, J. M., Goudemand, M., Toumi, M., Johnson, S., and Pettersson, Å. (1-9-2001). The European service mapping schedule (ESMS): a new instrument for mental health services research, results of a French study. *17th annual meeting of the International Society of Technology Assessment in Health Care (ISTAHC), June 3-6, 2001, Philadelphia, PA, USA*


C. Book Chapters Published or In Press


